304 related articles for article (PubMed ID: 32422250)
1. Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation.
Al Saleh AS; Sidiqi MH; Muchtar E; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1402-1405. PubMed ID: 32422250
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma.
Parmar H; Al Saleh AS; Visram A; Warsame R; Kourelis T; Gonsalves W; Dingli D; Muchtar E; Hayman S; Kapoor P; Buadi F; Dispenzieri A; Lacy M; Gertz M; Kumar S
Transplant Cell Ther; 2021 Apr; 27(4):309.e1-309.e5. PubMed ID: 33836869
[TBL] [Abstract][Full Text] [Related]
4. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
5. Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation.
Hwa YL; Kumar SK; Gertz MA; Lacy MQ; Buadi FK; Kourelis TV; Gonsalves WI; Rajkumar SV; Go RS; Leung N; Kapoor P; Dingli D; Kyle RA; Russell S; Lust JA; Hayman SR; Lin Y; Zeldenrust S; Dispenzieri A
Am J Hematol; 2016 Oct; 91(10):984-8. PubMed ID: 27341539
[TBL] [Abstract][Full Text] [Related]
6. Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Stella-Holowiecka B; Czerw T; Holowiecka-Goral A; Giebel S; Wojnar J; Holowiecki J
Transplant Proc; 2007 Nov; 39(9):2893-7. PubMed ID: 18022010
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of post-transplant bone marrow plasma cell percent in multiple myeloma patients undergone autologous transplantation.
Hwang IH; Chung JS; Shin HJ; Choi YJ; Song MK; Seol YM; Cho GJ; Choi BG; Choi MK; Choi BK; Ahn KH; Shin KH; Lee HS; Nam HS; Hwang JM
Korean J Intern Med; 2011 Mar; 26(1):76-81. PubMed ID: 21437166
[TBL] [Abstract][Full Text] [Related]
8. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
[TBL] [Abstract][Full Text] [Related]
9. Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival.
Tandon N; Muchtar E; Sidana S; Dispenzieri A; Lacy MQ; Dingli D; Buadi FK; Hayman SR; Chakraborty R; Hogan WJ; Gonsalves W; Warsame R; Kourelis TV; Leung N; Kapoor P; Kumar SK; Gertz MA
Bone Marrow Transplant; 2017 Aug; 52(8):1126-1132. PubMed ID: 28394369
[TBL] [Abstract][Full Text] [Related]
10. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
[TBL] [Abstract][Full Text] [Related]
12. The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients.
Huang X; Ren G; Chen W; Guo J; Zhao L; Zeng C; Ge Y; Liu Z
Amyloid; 2021 Jun; 28(2):75-83. PubMed ID: 33084412
[TBL] [Abstract][Full Text] [Related]
13. Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma.
Shin HJ; Kim K; Lee JW; Song MK; Lee JJ; Lee HS; Lee WS; Kim SJ; Chung JS
Eur J Haematol; 2014 Nov; 93(5):414-21. PubMed ID: 24813053
[TBL] [Abstract][Full Text] [Related]
14. Retrospective Analysis of Autologous Stem Cell Transplantation for AL Amyloidosis: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation.
Fuchida SI; Kawamura K; Sunami K; Tsukada N; Fujii S; Ohkawara H; Usuki K; Wake A; Endo S; Ishiyama K; Ueda Y; Nakamura Y; Miyamoto T; Fukuda T; Ichinohe T; Atsuta Y; Takamatsu H
Transplant Cell Ther; 2022 Feb; 28(2):76-82. PubMed ID: 34774818
[TBL] [Abstract][Full Text] [Related]
15. Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis.
Vaxman I; Sidiqi MH; Al Saleh AS; Kumar S; Muchtar E; Dispenzieri A; Buadi F; Dingli D; Lacy M; Hayman S; Leung N; Gonsalves W; Kourelis T; Warsame R; Hogan W; Gertz M
Bone Marrow Transplant; 2021 Apr; 56(4):928-935. PubMed ID: 33208916
[TBL] [Abstract][Full Text] [Related]
16. Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis.
Sidiqi MH; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Mar; 25(3):e108-e111. PubMed ID: 30529461
[TBL] [Abstract][Full Text] [Related]
17. Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP.
Hayashi T; Ikeda H; Igarashi T; Maruyama Y; Aoki Y; Nojima M; Ishida T; Shinomura Y
Int J Hematol; 2014 Dec; 100(6):554-8. PubMed ID: 25281404
[TBL] [Abstract][Full Text] [Related]
18. [Long-term follow-up of multiple myeloma after autologous hematopoietic stem cell transplantation: a single center results].
Sui WW; Zou DH; An G; Yi SH; Deng SH; Huang WY; Wang TY; Li J; Liu H; Fu MW; Lyu R; Liu W; Xu Y; Li ZJ; Zhao YZ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):499-504. PubMed ID: 28655093
[No Abstract] [Full Text] [Related]
19. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
20. Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis.
Abdallah N; Sidana S; Dispenzieri A; Lacy M; Buadi F; Hayman S; Kapoor P; Leung N; Dingli D; Hwa YL; Lust J; Russell S; Gonsalves W; Go R; Hogan W; Kyle R; Rajkumar SV; Gertz M; Kumar S
Bone Marrow Transplant; 2020 Jul; 55(7):1297-1304. PubMed ID: 32518290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]